Search Medical Condition
Please enter condition
Please choose location

Torremolinos, Spain Clinical Trials

A listing of Torremolinos, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (162) clinical trials

Clinical Effect Size of an Educational Intervention in the Home and Compliance on People Who Suffer From Stroke

Background. Stroke is the third leading cause of death and the leading cause of long-term neurological disability in the world. Cognitive, communication and physical weakness combined with environmental changes frequently cause changes in roles, routines and daily occupations. The educational intervention combines didactic and interactive intervention, which combines the best ...

Phase N/A

0.0 miles

Learn More »

Prospective Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy (MTM)

This is a prospective, non-interventional, longitudinal study of the natural history and function of approximately 60 patients with MTM from the United States, Canada and Europe. The duration of the study, including the enrollment period, will be 36 months. Data from the study will be used to characterize the disease ...

Phase N/A

2.64 miles

Learn More »

Prospective Natural History Study of Patients With Myotubular Myopathy and Other CentroNuclear Myopathies

This is the 2 years extension of the European part of the prospective and longitudinal study of the natural history and function of patients with myotubular myopathy (MTM) initially sponsored by Valerion therapeutics. Twenty additional patients with other centronuclear myopathies (CNM) (due to mutation in MTM1 but also in DNM2 ...

Phase N/A

2.64 miles

Learn More »

Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix During Pregnancy or Immediately Post-delivery

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' Infanrix hexa, given in the primary vaccination schedule to infants born to pregnant women who participated in study 116945 [DTPA (BOOSTRIX)-047]. This study will help us evaluate if the presence of transplacentally transferred maternal antibodies ...

Phase

4.46 miles

Learn More »

Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix During Pregnancy or Immediately Post-delivery

The purpose of this study is to assess the immunogenicity and safety of the Infanrix hexa booster dose given at 11-18 months of age to infants who received primary vaccination at 6-14 weeks. All infants in this booster study were born to pregnant women who participated in the study 116945 ...

Phase

4.46 miles

Learn More »

Safety and Tolerability Pharmacokinetics (PK) Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)

This study is the first study with GSK2982772, a receptor-interacting protein-1 (RIP1) kinase inhibitor, in subjects with moderate to severe RA who are currently being treated with disease modifying anti-rheumatic drugs (DMARDs). The primary objective of the study is to investigate the safety and tolerability of repeat oral doses of ...

Phase

4.46 miles

Learn More »

Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563) in Healthy Infants Starting at Age 6-12 Weeks

Experimental design: Phase IIIA, observer-blind, randomised (1:1:1:1), controlled, multi-centric, with four parallel groups and a staggered enrolment (Part A and Part B). Duration of the study: The intended duration of the study, per subject, will be approximately 7-8 months including the 6 months of extended safety follow-up period after the ...

Phase

4.46 miles

Learn More »

Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia

This is a non-interventional, multi-centre, longitudinal observation with a defined population using a prospective cohort design to estimate the incidence of Pure Red Cell Aplasia (PRCA), neutralising antibodies, lack of efficacy, and thromboembolic events under treatment with Retacrit (epoetin zeta) administered subcutaneously in patients with renal anaemia.

Phase N/A

5.11 miles

Learn More »

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

To assess whether a rivaroxaban-based anticoagulation strategy, following successful TAVR, compared to an antiplatelet-based strategy, is superior in reducing death or first thromboembolic events (DTE). To assess the primary bleeding events (PBE) of the rivaroxaban-based strategy compared to an antiplateletbased strategy, following TAVR.

Phase

7.17 miles

Learn More »

Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)

The purpose of this study is to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) subjects with Programmed death ligand 1+ (PD-L1+) tumors

Phase

7.17 miles

Learn More »